The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2– locally advanced/metastatic breast cancer (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer study.
 
Mafalda Oliveira
Honoraria - AstraZeneca; Curio Science; Eisai; Gilead Sciences; i-One; Libbs; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD; Pfizer; ProteinQure; Relay Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Immutep (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - President elected, SOLTI Cancer Research Group
 
Amir Sonnenblick
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Progenetics; Rhenium Medical; Roche; Stemline Therapeutics
Speakers' Bureau - Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Medison; MSD; NeoPharm; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Salomon Stemmer
Stock and Other Ownership Interests - canfite; CTG Pharma; DocBoxMD; peersMD; Remiwise; tyrnovo; VYPE
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); GEICAM (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); most pharma companies running studies as PI or CI (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Taiga (Inst); Teva (Inst); Tiziana Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - check point inhibitors; combo patent; ctg; vype
 
Maria Gion
Consulting or Advisory Role - AstraZeneca; Gilead Sciences
Speakers' Bureau - AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
(OPTIONAL) Uncompensated Relationships - Roche
 
Begona Bermejo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; F. Hoffmann-La Roche Ltd/ Genentech, Inc.; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Einav Gal Yam
Honoraria - AstraZeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; MSD; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Seth Wander
Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Genentech/Roche; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Regor Therapeutics; Veracyte
Speakers' Bureau - 2nd.MD; Guardant Health; Lilly
Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Inocras (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Clélia Cahuzac
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Annie Collier
Employment - Genentech/Roche
Stock and Other Ownership Interests - Roche
Research Funding - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Huy Ngo
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Anne-Cecile Retiere
Employment - Roche
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Richard Schwab
Employment - Genentech/Roche
Stock and Other Ownership Interests - Biosplice (I); Roche/Genentech
Research Funding - Genentech/Roche
 
Jing Zhu
Employment - Genentech
Stock and Other Ownership Interests - Roche
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca Canada; Bixink; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Everest Medicine; Merck; MSD; Novartis; Pfizer; Roche; Takeda
(OPTIONAL) Uncompensated Relationships - Research funding in the form of third-party medical writing support, furnished by Chantel Swart, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.